U.S., July 31 -- ClinicalTrials.gov registry received information related to the study (NCT07093268) titled 'Safety of Intrathecal Riluzole in Patients With Amyotrophic Lateral Sclerosis' on May 08, 2024.
Brief Summary: The purpose of this study is to investigate the safety and tolerability of intrathecal riluzole in adults with amyotrophic lateral sclerosis.
Study Start Date: Aug. 15
Study Type: INTERVENTIONAL
Condition:
Amyotrophic Lateral Sclerosis
Motor Neuron Disease
Intervention:
DRUG: Intrathecal Riluzole
Intrathecal infusion of riluzole for 6 weeks followed by 6 months treatment with safety committee approval.
Recruitment Status: NOT_YET_RECRUITING
Sponsor: Brain Trust Bio
Published by HT Digital Content Services with per...